This reflects the state of play as of early 2026: States that cover GLP-1s for obesity treatment (fee-for-service): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, Washington approximately 13 states total as of January 2026
A retrospective, population-based cohort study found that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was safe and associated with lower risks of cardiovascular or psychiatric comorbidities and lower mortality among patients with psoriasis
These effects are proposed to be due to anti-inflammatory, autophagic flux activation, and inflammasome suppression [272]
Oral medications and topical creams may work in some cases, or you may choose a permanent solution with one of the different kinds of hair transplants